Rosuvastatin reduces LDL production and the number of LDL particles.
Rosuvastatin, an HMG CoA-reductase inhibitor (statin), and Ezetimibe, a dietary cholesterol absorption inhibitor, combination is indicated in adults:
Rosuvastatin: Rosuvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell-surface to enhance uptake and catabolism of LDL; Rosuvastatin reduces LDL production and the number of LDL particles.
The concomitant use of Rosuvastatin & Ezetimibe combination with Cyclosporine or Gemfbrozil is not recommended.Rosuvastatin & Ezetimibe combination dosage modifcations are recommended for patients taking certain antiviral medications, Darolutamide, and Regorafenib.
Contraindicated in patients with:Active liver disease or decompensated cirrhosisHypersensitivity to any component
Common side efects are headache, nausea, myalgia, arthralgia, dizziness, asthenia, constipation, abdominal pain, respiratory tract infection, diarrhea, sinusitis, pain in extremity, fatigue, infuenza and back pain.
This preparation is contraindicated in women who are or may become pregnant. Breastfeeding is not recommended.
Myopathy and rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs and higher dosage. Discontinue if markedly elevated creatine kinase (CK) levels occur or myopathy is diagnosed or suspected.
Patients with Hepatic Impairment: Contraindicated in patients with acute liver failure or decompensated cirrhosis. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue the medicine.
Other lipid regulating drugs
Store below 30°C. Protect from light and moisture. Keep all medicine out of the reach of children.
